Evidence map›Paper›PMID 26962021›Full record

ReviewBiochimica et biophysica acta2016

Nuclear receptors and nonalcoholic fatty liver disease.

Matthew C Cave, Heather B Clair, Josiah E Hardesty, K Cameron Falkner, Wenke Feng, Barbara J Clark, Jennifer Sidey, Hongxue Shi, Bashar A Aqel, Craig J McClain and 1 more

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 1 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 1 synthesis or guideline pooled it, 275 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. RXRActa pharmaceutica Sinica. B · 2025
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Matthew C CaveDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville School of Medicine, Louisville, KY 40202, USA; Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY 40202, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; The Robley Rex Veterans Affairs Medical Center, Louisville, KY 40206, USA; The KentuckyOne Health Jewish Hospital Liver Transplant Program, Louisville, KY 40202, USA. Electronic address: matt.cave@louisville.edu.
Heather B ClairDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Josiah E HardestyDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY 40202, USA.
K Cameron FalknerDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Wenke FengDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville School of Medicine, Louisville, KY 40202, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Barbara J ClarkDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Jennifer SideyDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Hongxue ShiDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Bashar A AqelDepartment of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Scottsdale, AZ 85054, USA.
Craig J McClainDepartment of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville School of Medicine, Louisville, KY 40202, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA; The Robley Rex Veterans Affairs Medical Center, Louisville, KY 40206, USA; The KentuckyOne Health Jewish Hospital Liver Transplant Program, Louisville, KY 40202, USA.
Russell A ProughDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY 40202, USA.
University of Louisville · USJewish Hospital · USMayo Clinic in Arizona · US

Funding

Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI BARVE, SHIRISH S · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN · 2016 to 2026
$17.9M
UOFL ENVIRONMENTAL HEALTH SCIENCES TRAINING PROGRAMT32ES011564 · NIEHS · UNIVERSITY OF LOUISVILLE · PI David W Hein, John Pierce Wise · 2004 to 2026
$7.1M
Mechanisms of Probiotics in Alcoholic Liver DiseaseR01AA023190 · NIAAA · UNIVERSITY OF LOUISVILLE · PI FENG, WENKE · 2015 to 2024
$3.5M
PCBs worsen obesity/metabolic syndrome through 'toxic metabolic endotoxemia'R01ES021375 · NIEHS · UNIVERSITY OF LOUISVILLE · PI CAVE, MATTHEW C · 2012 to 2016
$1.7M
Mechanisms for alcohol induced gut barrier dysfunction in ALDR01AA023681 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2014 to 2018
$1.6M
Novel therapies in alcoholic hepatitis University of LouisvilleU01AA021901 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2012 to 2017
$1.5M
Zinc supplementation in alcoholic cirrhosisK23AA018399 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CAVE, MATTHEW C · 2010 to 2014
$1.0M
Summer Environmental Health Sciences Training ProgramT35ES014559 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Matthew C Cave, Daniel Joseph Conklin · 2006 to 2026
$751k
FGF21 and adipose lipolysis in alcoholic fatty liverR21AA022416 · NIAAA · UNIVERSITY OF LOUISVILLE · PI FENG, WENKE · 2014 to 2015
$388k
Xenobiotic Receptors Modulate PCB-induced SteatohepatitisF30ES025099 · NIEHS · UNIVERSITY OF LOUISVILLE · PI CLAIR, HEATHER B · 2015 to 2018
$167k
Polychlorinated biphenyls act through EGFR to worsen NAFLDF31ES028982 · NIEHS · UNIVERSITY OF LOUISVILLE · PI HARDESTY, JOSIAH E · 2017 to 2018
$43k
NIAAA NIH HHS K23 AA018399NIAAA NIH HHS P50 AA024337NIAAA NIH HHS R01 AA023190NIAAA NIH HHS R01 AA023681NIAAA NIH HHS R21 AA022416NIAAA NIH HHS U01 AA021901NIEHS NIH HHS F30 ES025099NIEHS NIH HHS F31 ES028982NIEHS NIH HHS R01 ES021375NIEHS NIH HHS R13 ES024661NIEHS NIH HHS T32 ES011564NIEHS NIH HHS T35 ES014559NIGMS NIH HHS P20 GM113226
6 · The paper itself

Abstract

Nuclear receptors are transcription factors which sense changing environmental or hormonal signals and effect transcriptional changes to regulate core life functions including growth, development, and reproduction. To support this function, following ligand-activation by xenobiotics, members of subfamily 1 nuclear receptors (NR1s) may heterodimerize with the retinoid X receptor (RXR) to regulate transcription of genes involved in energy and xenobiotic metabolism and inflammation. Several of these receptors including the peroxisome proliferator-activated receptors (PPARs), the pregnane and xenobiotic receptor (PXR), the constitutive androstane receptor (CAR), the liver X receptor (LXR) and the farnesoid X receptor (FXR) are key regulators of the gut:liver:adipose axis and serve to coordinate metabolic responses across organ systems between the fed and fasting states. Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease and may progress to cirrhosis and even hepatocellular carcinoma. NAFLD is associated with inappropriate nuclear receptor function and perturbations along the gut:liver:adipose axis including obesity, increased intestinal permeability with systemic inflammation, abnormal hepatic lipid metabolism, and insulin resistance. Environmental chemicals may compound the problem by directly interacting with nuclear receptors leading to metabolic confusion and the inability to differentiate fed from fasting conditions. This review focuses on the impact of nuclear receptors in the pathogenesis and treatment of NAFLD. Clinical trials including PIVENS and FLINT demonstrate that nuclear receptor targeted therapies may lead to the paradoxical dissociation of steatosis, inflammation, fibrosis, insulin resistance, dyslipidemia and obesity. Novel strategies currently under development (including tissue-specific ligands and dual receptor agonists) may be required to separate the beneficial effects of nuclear receptor activation from unwanted metabolic side effects. The impact of nuclear receptor crosstalk in NAFLD is likely to be profound, but requires further elucidation. This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr. Wen Xie.

Indexed as

Adipose TissueAnimalsConstitutive Androstane ReceptorDrugs, InvestigationalEnergy MetabolismGene Expression RegulationHumansLiverLiver X ReceptorsNon-alcoholic Fatty Liver DiseasePeroxisome Proliferator-Activated ReceptorsPregnane X ReceptorReceptor Cross-TalkReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearReceptors, SteroidConstitutive Androstane ReceptorDrugs, InvestigationalLiver X ReceptorsPeroxisome Proliferator-Activated ReceptorsPregnane X ReceptorReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and NuclearReceptors, SteroidXenobioticsCARFXRLXRNAFLDNASHPCBsPPARPXRTAFLDTASH

Identifiers

PMID26962021
PMCPMC5149456
OpenAlexW2293546533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.